Rapport Therapeutics Shares Surge After Phase 2 Trial Success
Rapport Therapeutics reported a successful Phase 2 trial, prompting a surge in its shares. The source frames the opportunity as potentially worth $1 billion.
Rapport Therapeutics reported a successful Phase 2 trial, prompting a surge in its shares. The source frames the opportunity as potentially worth $1 billion.